HIV treatment reduces risk of malaria recurrence in children, study shows
A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health.
The combination of protease inhibitors lopinavir and ritonavir contributed to an overall reduction of 40 percent in the rate of malaria among a group of HIV-positive infants and children up to 6 years old in Uganda who were also being treated with anti-malarial drugs. This reduction was in comparison to malaria incidence among children receiving a drug treatment of one of a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Protease inhibitors interfere with the reproduction of HIV by blocking the protease enzyme of HIV. The protease inhibitor combination used in the study did not appear to inhibit an initial bout of malaria—but reduce the chances of a recurrence of the disease following a successful treatment.
The researchers found that blood levels of anti-malarial drugs were higher in children who had received the protease inhibitors, which may help explain their effectiveness at preventing malaria's return.
"It's possible that these protease inhibitors prevent antimalarial drugs from breaking down or have some other additive effect against the malarial parasite," said Lynne Mofenson, M.D., chief of the Pediatric, Adolescent, and Maternal AIDS Branch at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the NIH institute that funded the study. "Laboratory studies also suggest that protease inhibitors can block the malaria parasite outright. Finding out why this drug combination is effective is an area for further study."
Previous studies have shown that the lopinavir–ritonavir combination also is more effective for treating HIV-positive infants than widely used treatment regimens based on the medication nevirapine.
The NNRTI nevirapine is the first-line treatment for HIV recommended by the World Health Organization for children in developing countries. It is less expensive than the protease inhibitor combination and, unlike the protease inhibitors, does not need refrigeration. Compared to nevirapine, the liquid formulation of the protease inhibitor combination is also unpleasant tasting. However, recent changes in the protease inhibitor formulation may overcome these barriers to expanding its use in resource poor settings, Dr. Mofenson said.
"New formulations have been developed for the drug so that it can be sprinkled on food, tastes better, and doesn't need refrigeration," she said. "This may help where it is needed most."
First author Jane Achan, MMed, of Makerere University and the Infectious Diseases Research Collaboration, in Uganda, collaborated with colleagues in Uganda and at the University of California, San Francisco.
Their findings appear in the New England Journal of Medicine.
More than 170 HIV-positive infants and children participated in the study. They received either an NNRTI (nevirapine for children under age 3, efavirenz for children over age 3) or the protease inhibitor-based treatment. In addition, the children received insecticide-treated nets to keep mosquitoes away while they slept, vitamins, a clean source of water, and medication to prevent infection with the malaria parasite, which is transmitted by mosquitoes.
Even with these measures, the researchers found that the children's risk of developing malaria in the first six months of their anti HIV treatment was greater than 40 percent. Although the risk was slightly higher in the nevirapine-treated group, the difference was not significant statistically.
However, of the children who developed malaria and were successfully treated for it during the study, 41 percent of those taking an NNRTI developed another case of malaria within 28 days of clearing their system of the parasite the first time. In contrast, only 14 percent of those on the combination lopinavir–ritonavir treatment developed another case of malaria within this time period.
When comparing the two groups over a 63-day period, the researchers found that 54 percent of the NNRTI group had a recurrence of malaria, compared with 28 percent of the group taking the lopinavir–ritonavir treatment.
In addition, tests conducted one week after the start of malaria treatment showed that blood levels of an anti-malaria drug were higher among children receiving the protease inhibitor combination than among their counterparts taking the nevirapine-based treatment.
"The finding that this protease inhibitor combination not only appears more effective at treating HIV than NNRTIs, but also protects against malaria recurrence, merits its consideration for children living in areas where malaria is rampant," Dr. Mofenson said.
Journal reference: New England Journal of Medicine
- NIH studies influence revision of WHO guidelines for treating HIV-infected women, infants Oct 13, 2010 | not rated yet | 0
- Certain HIV medication associated with adrenal dysfunction in newborns of HIV-1 infected mothers Jul 05, 2011 | not rated yet | 0
- Drug designer: New tool reveals mutations that cause HIV-drug resistance Jul 08, 2011 | not rated yet | 0
- HIV drug resistance lasts about one year in women treated with nevirapine to prevent infant infection Feb 16, 2010 | not rated yet | 0
- Cholesterol levels elevated in toddlers taking anti-HIV drugs Nov 22, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
As the world prepares for what may be the next pandemic strain of influenza virus, in the H7N9 bird flu, a new UC Irvine study reveals that the 2009 H1N1 swine flu pandemic was deadliest for people under the age of 65, while ...
Diseases, Conditions, Syndromes 9 hours ago | not rated yet | 0
The World Health Organization says the Horn of Africa is experiencing an outbreak of polio with cases confirmed in Kenya and Somalia.
Diseases, Conditions, Syndromes 10 hours ago | not rated yet | 0
A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.
Diseases, Conditions, Syndromes 10 hours ago | not rated yet | 0
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
Diseases, Conditions, Syndromes 10 hours ago | not rated yet | 0 |
Patients with underlying heart failure are more likely to experience adverse outcomes from mild hypothyroidism, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & ...
Diseases, Conditions, Syndromes 12 hours ago | not rated yet | 0
Existing research shows that bicyclists who wear helmets have an 88 percent lower risk of brain injury, but researchers at Boston Children's Hospital found that simply having bicycle helmet laws in place showed a 20 percent ...
2 hours ago | not rated yet | 0
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
13 hours ago | 4.9 / 5 (7) | 0 |
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
13 hours ago | 4 / 5 (1) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
10 hours ago | 5 / 5 (2) | 2 |
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
10 hours ago | 4 / 5 (2) | 0 |
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...
12 hours ago | 5 / 5 (1) | 0 |